How this company measures up on the fundamentals that matter
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Trading at $30 against a fair value of $56, a 47% discount. Passes all ethical screens. Ranks better than 94% of screened stocks.
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Trading characteristics and market positioning
Balance sheet strength and cash generation — the foundation of long-term value
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-21 | RIEDEL NORBERT G | Director | 32,155 | $260,605 | |
| 2026-02-03 | RIEDEL NORBERT G | Director | 30,000 | $132,600 | |
| 2025-08-20 | GRUBER JAMES R | Chief Financial Officer | 41,713 | $673,714 | |
| 2025-06-16 | KREMPA DAVID | Officer | 34,000 | $504,318 | |
| 2025-06-10 | OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | 7,930 | $125,484 | |
| 2025-06-05 | BRYNJELSEN SEAN E | Chief Executive Officer | 210,000 | $3,592,611 | |
| 2025-01-03 | RIEDEL NORBERT G | Director | 102,400 | $373,842 | |
| 2024-10-23 | OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | 10,000 | $79,814 | |
| 2024-10-08 | OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | 62,070 | $434,137 | |
| 2024-09-11 | OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | 107,500 | $504,875 |
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15